These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 23966480)

  • 1. Chemical stability of extemporaneously compounded omeprazole formulations: a comparison of two methods of compounding.
    Garg S; Svirskis D; Al-Kabban M; Farhan S; Komeshi M; Lee J; Liu Q; Naidoo S; Kairuz T
    Int J Pharm Compd; 2009; 13(3):250-3. PubMed ID: 23966480
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Effect of Manufacturer on the Compounding of Omeprazole Suspensions and Their Stability Assessment.
    Meissner S; Bansal M; Dela CPD; Hanning S; Svirskis D
    Int J Pharm Compd; 2020; 24(2):140-147. PubMed ID: 32196476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stability of two concentrations of tiagabine in an extemporaneously compounded suspension.
    Haase MR; Khan MA; Bonilla J
    Int J Pharm Compd; 2003; 7(6):485-9. PubMed ID: 23979810
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stability of melatonin in an extemporaneously compounded sublingual solution and hard gelatin capsule.
    Haywood A; Burrell A; Breda Kv; George R; Testa C; Norris R
    Int J Pharm Compd; 2009; 13(2):170-4. PubMed ID: 23970011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Temozolomide stability in extemporaneously compounded oral suspensions.
    Trissel LA; Zhang Y; Koontz SE
    Int J Pharm Compd; 2006; 10(5):396-9. PubMed ID: 23974320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stability of partial doses of omeprazole-sodium bicarbonate oral suspension.
    Johnson CE; Cober MP; Ludwig JL
    Ann Pharmacother; 2007 Dec; 41(12):1954-61. PubMed ID: 17956960
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stability of omeprazole in an extemporaneously prepared oral liquid.
    Quercia RA; Fan C; Liu X; Chow MS
    Am J Health Syst Pharm; 1997 Aug; 54(16):1833-6. PubMed ID: 9269520
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stability of sotalol hydrochloride in extemporaneously prepared oral suspension formulations.
    Sidhom MB; Rivera N; Almoazen H; Taft DR; Kirschenbaum HL
    Int J Pharm Compd; 2005; 9(5):402-6. PubMed ID: 23925139
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stability of an extemporaneously compounded clonidine hydrochloride oral liquid.
    Levinson ML; Johnson CE
    Am J Hosp Pharm; 1992 Jan; 49(1):122-5. PubMed ID: 1570852
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stability of an extemporaneously compounded baclofen oral liquid.
    Johnson CE; Hart SM
    Am J Hosp Pharm; 1993 Nov; 50(11):2353-5. PubMed ID: 8266961
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stability of extemporaneously compounded spironolactone suspensions.
    Mathur LK; Wickman A
    Am J Hosp Pharm; 1989 Oct; 46(10):2040-2. PubMed ID: 2816959
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Compatibility of Flavoring Agents in Compounding Extemporaneous Omeprazole Oral Liquid.
    Chuong M; Taglieri CA; Huang SY; Sariol A; Kitigawa R; Barman K; Mistry A; Harris DL; Kerr SG
    Int J Pharm Compd; 2019; 23(6):504-510. PubMed ID: 31751947
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stability of an extemporaneously compounded terbutaline sulfate oral liquid.
    Horner RK; Johnson CE
    Am J Hosp Pharm; 1991 Feb; 48(2):293-5. PubMed ID: 2003504
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stability of omeprazole in SyrSpend SF Alka (reconstituted).
    Whaley PA; Voudrie MA; Sorenson B
    Int J Pharm Compd; 2012; 16(2):164-6. PubMed ID: 23050328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Naratriptan hydrochloride in extemporaneosly compounded oral suspensions.
    Zhang YP; Trissel LA; Fox JL
    Int J Pharm Compd; 2000; 4(1):69-71. PubMed ID: 23985892
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Influence of Tablet Formulation, Drug Concentration, and pH Modification on the Stability of Extemporaneously Compounded Levothyroxine Suspensions.
    Svirskis D; Lin SW; Brown H; Sangaroomthong A; Shin D; Wang Z; Xu H; Dean R; Vareed P; Jensen M; Wu Z
    Int J Pharm Compd; 2018; 22(2):164-171. PubMed ID: 29877863
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stability of Compounded Ursodiol Suspensions in PCCA Base, SuspendIt.
    Pramar YV; Mandal TK; Bostanian LA; Nguyen AT; Miller V; Morris TC; Graves RA
    Int J Pharm Compd; 2019; 23(1):70-76. PubMed ID: 30668538
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of an extemporaneous liquid formulation of lisinopril.
    Thompson KC; Zhao Z; Mazakas JM; Beasley CA; Reed RA; Moser CL
    Am J Health Syst Pharm; 2003 Jan; 60(1):69-74. PubMed ID: 12533979
    [TBL] [Abstract][Full Text] [Related]  

  • 19. To Flavor or Not to Flavor Extemporaneous Omeprazole Liquid.
    Chuong MC; Taglieri CA; Kerr SG
    Int J Pharm Compd; 2017; 21(6):500-512. PubMed ID: 29220339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative Stability of Compounded Omeprazole Suspension Versus Commercial Omeprazole Kit When Stored in Oral Syringes Under Refrigerated Conditions.
    Jackson R; Lewis P; Brown SD
    J Pharm Technol; 2020 Oct; 36(5):179-186. PubMed ID: 34752549
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.